ArticleScience translational medicine2013

Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome.

Rajendra Kedlaya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.